^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Cancer

    Related cancers:
    4d
    Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. (PubMed, BMC Med)
    IBI389 showed manageable safety profiles in patients with advanced solid tumors and preliminary efficacy in Claudin18.2-positive patients with GC/GEJC.
    P1 data • Journal
    |
    CLDN18 (Claudin 18)
    |
    IBI-389
    6d
    A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397
    6d
    Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease (clinicaltrials.gov)
    P1, N=32, Recruiting, Washington University School of Medicine | N=16 --> 32
    Enrollment change
    |
    Signatera™
    |
    Hiltonol (poly-ICLC)
    7d
    First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=163, Active, not recruiting, TORL Biotherapeutics, LLC | Recruiting --> Active, not recruiting | N=70 --> 163 | Trial primary completion date: Feb 2026 --> Jun 2026
    Enrollment closed • Enrollment change • Trial primary completion date • First-in-human
    7d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    8d
    Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma. (PubMed, Expert Rev Anticancer Ther)
    Zolbetuximab exemplifies a novel therapeutic class which can be classified as targeted cytolytic antibodies. Future work should test combinations with checkpoint blockade, refine biomarkers and define resistance mechanisms.
    Review • Journal • IO biomarker
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    Vyloy (zolbetuximab-clzb)
    12d
    sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) (clinicaltrials.gov)
    P2, N=38, Recruiting, Rutgers, The State University of New Jersey | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    13d
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
    P1, N=126, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=180 --> 126
    Enrollment closed • Enrollment change
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    MSI-H/dMMR • BRAF mutation • BRCA mutation
    |
    Keytruda (pembrolizumab) • KFA115
    14d
    Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study (clinicaltrials.gov)
    P=N/A, N=9600, Recruiting, Natera, Inc.
    New trial
    15d
    Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=53, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • HEOR
    16d
    Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers. (PubMed, Cancer)
    ctDNA dynamics predicted progression and may guide treatment or imaging. ctDNA offers a minimally invasive, cost-effective adjunct to radiographic surveillance.
    Retrospective data • Journal • Circulating tumor DNA
    |
    Signatera™
    18d
    Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy (clinicaltrials.gov)
    P=N/A, N=28, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 28
    Enrollment closed • Enrollment change